title: Antibiotic and antimicrobial peptide combinations: synergistic inhibition of Pseudomonas fluorescens and antibiotic-resistant variants.
abstract: Variants resistant to penicillin G (RvP), streptomycin (RvS), lincomycin (RvL) and rifampicin (RvR) were developed from a colistin-sensitive isolate of Pseudomonas fluorescens LRC-R73 (P. fluorescens). Cell fatty acid composition, K(+) efflux and sensitivity to antimicrobial peptides (nisin Z, pediocin PA-1/AcH and colistin) alone or combined with antibiotics were determined. P. fluorescens was highly sensitive to kanamycin, tetracycline and chloramphenicol at minimal inhibitory concentrations of 0.366, 0.305 and 0.732 μg/ml respectively. P. fluorescens, RvP, RvS, RvL and RvR were resistant to nisin Z and pediocin PA-1/AcH at concentrations ≥100 μg/ml but sensitive to colistin at 0.076, 0.043, 0.344, 0.344 and 0.258 μg/ml respectively. A synergistic inhibitory effect (FICI ≤0.5) was observed when resistant variants were treated with peptide/antibiotic combinations. No significant effect on K(+) efflux from the resistant variants in the presence of antibiotics or peptides alone or combined was observed. The proportion of C16:0 was significantly higher in antibiotic-resistant variants than in the parent strain, accounting for 32.3%, 46.49%, 43.3%, 40.1% and 44.1% of the total fatty acids in P. fluorescens, RvP, RvS, RvL and RvR respectively. Combination of antibiotics with antimicrobial peptides could allow reduced use of antibiotics in medical applications and could help slow the emergence of bacteria resistant to antibiotics.
authors.affiliation: Lethbridge Research Center, Agricultureg and Agri-Food Canada, Lethbridge, AB, Canada. karim.naghmouchi@gmail.com
authors.forename: Karim
authors.initials: K
authors.lastname: Naghmouchi
authors.forename: Christophe
authors.initials: C
authors.lastname: Le Lay
authors.forename: John
authors.initials: J
authors.lastname: Baah
authors.forename: Djamel
authors.initials: D
authors.lastname: Drider
mesh_terms: D000617:Aminoglycosides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001430:Bacteriocins / Q000494:pharmacology; D002701:Chloramphenicol / Q000494:pharmacology; D003091:Colistin / Q000494:pharmacology; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics*; D008034:Lincomycin / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D010406:Penicillins / Q000494:pharmacology; D011188:Potassium / Q000378:metabolism; D011551:Pseudomonas fluorescens / Q000187:drug effects* / Q000235:genetics*; D012293:Rifampin / Q000494:pharmacology; D013752:Tetracycline / Q000494:pharmacology
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D001430:Bacteriocins; D010406:Penicillins; D002701:Chloramphenicol; D008034:Lincomycin; D013752:Tetracycline; D011188:Potassium; D012293:Rifampin; D003091:Colistin